Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07163637 · ClinicalTrials.gov registry record · NA
Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort
A NA study of Healthy Participants and Upper Gastrointestinal Discomfort, sponsored by Novozymes A/S.
- Recruiting
- Registry status
- NA
- Development phase
- 324
- Enrollment target
- 1
- Study location
NCT07163637 is a NA study of Healthy Participants and Upper Gastrointestinal Discomfort that is actively recruiting participants, run by Novozymes A/S. The registered enrollment target is 324 participants, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (414% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07163637, a NA study of Healthy Participants and Upper Gastrointestinal Discomfort, is actively recruiting participants, sponsored by Novozymes A/S.
- RECRUITING
- Registry status
- NA
- Development phase
- 324 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the food supplement containing a postbiotic (inanimate) Limosilactobacillus reuteri DSM 17648 works to improve the symptoms of upper gastrointestinal discomfort in healthy adults. The main questions it aims to answer are: 1. Does L. reuteri DSM 17648 reduce the frequency of the symptoms of upper gastrointestinal discomfort, including acid reflux-related and dyspeptic symptoms, and its relief rate, over 8 weeks of intake? 2. Does L. reuteri DSM 17648 improve gastrointestinal-related quality of life, and perceived stress? 3. How well do participants tolerate the L. reuteri DSM 17648 supplement? 4. Does L. reuteri DSM 17648 have an effect on the gut microbiota? (Exploratory aim) Researchers will compare supplement containing L. reuteri DSM 17648 to a placebo (a look-alike supplement capsule that contains no L. reuteri DSM 17648). Participants will: * Take L. reuteri DSM 17648 supplement or a placebo every day for 8 weeks * Answer questionnaires once every 2 weeks * Provide stool samples for microbiome assessment at 2 timepoints (baseline and end of study (8 weeks)) * provide weekly information on investigational product intake and any adverse event records
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Limosilactobacillus reuteri DSM 17648
Study Locations (1)
Nevada
- Citruslabs - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2025-09-08 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07163637
The ClinicalTrials.gov registry entry for NCT07163637 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (414% higher). The listed sponsor is Novozymes A/S, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07163637 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.
Frequently Asked Questions
What is clinical trial NCT07163637 about?
NCT07163637 is a clinical study titled "Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort". The goal of this clinical trial is to learn if the food supplement containing a postbiotic (inanimate) Limosilactobacillus reuteri DSM 17648 works to improve the symptoms of upper gastrointestinal discomfort in healthy adults. The main questions it aims to answer are: 1. Does L. reuteri DSM 17648 r...
What is the current status of trial NCT07163637?
This trial is currently recruiting. It is a NA study. The enrollment target is 324 participants. The study started on 2025-09-08. Estimated completion is 2026-03-31.
What conditions does trial NCT07163637 study?
This clinical trial studies the following conditions: Healthy Participants, Upper Gastrointestinal Discomfort.
What interventions are being tested in trial NCT07163637?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Limosilactobacillus reuteri DSM 17648 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07163637?
This trial is sponsored by Novozymes A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07163637 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
RECRUITING · NA
-
Fructose Intestinal Gluconeogenesis
RECRUITING · NA
-
Royal Ancient Oats™ Study
RECRUITING · NA
-
The Increasing Mindfulness Engagement Project
RECRUITING · NA
-
Testing a Non-Invasive Spinal Stimulation Device
RECRUITING · NA
-
Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.